Top Pharmaceuticals
Page 1 of 1
Top Pharmaceuticals
2009 Top 20 Pharmaceutical Companies Report
They don’t call them “Big Pharma” for nothing! Several of the industry’s biggest players decided to get bigger via M&A this year, which means next year’s ranks are going to feature at least three new players, once Wyeth and Schering-Plough are swallowed up and Roche moves over to the Top Biopharma ranks. And I do mean top!
It’s a good thing my “Pharm System” has a whole crop of new companies to move into the ranks — you're on deck, Gilead! — but how will all these mergers and consolidations affect contract service providers? Columnist Michael Martorelli has some thoughts on the subject in this issue, but pharma companies remain quiet about how they’ll reconcile their internal mega-networks with their outsourcing strategies. So stay tuned . . .
—Gil Y. Roth, Editor
Top 20 Pharmaceutical Companies
01 Pfizer $44,174
02 Sanofi-Aventis $40,562
03 GlaxoSmithKline $37,810
04 Novartis $35,647
05 AstraZeneca $30,677
06 Merck $25,901
07 Johnson & Johnson $24,567
08 Roche $23,624
09 Eli Lilly & Co. $19,285
10 Bristol-Myers Squibb $17,715
11 Wyeth $17,391
12 Schering-Plough $16,534
13 Abbott Laboratories $16,013
14 Takeda $13,841
15 Bayer Schering $13,803
16 Boehringer Ingelheim $13,405
17 Teva* 10,482
18 Astellas* $9,646
19 Daiichi-Sankyo* $7,900
20 Eisai* $7,612
Based on 2008 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the pipeline and patent expiry info, download the PDFs of the profiles, available within each company's page.
* PDF profiles only available for companies 17-20
Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Bayer-Schering, by Kristin Brooks.
They don’t call them “Big Pharma” for nothing! Several of the industry’s biggest players decided to get bigger via M&A this year, which means next year’s ranks are going to feature at least three new players, once Wyeth and Schering-Plough are swallowed up and Roche moves over to the Top Biopharma ranks. And I do mean top!
It’s a good thing my “Pharm System” has a whole crop of new companies to move into the ranks — you're on deck, Gilead! — but how will all these mergers and consolidations affect contract service providers? Columnist Michael Martorelli has some thoughts on the subject in this issue, but pharma companies remain quiet about how they’ll reconcile their internal mega-networks with their outsourcing strategies. So stay tuned . . .
—Gil Y. Roth, Editor
Top 20 Pharmaceutical Companies
01 Pfizer $44,174
02 Sanofi-Aventis $40,562
03 GlaxoSmithKline $37,810
04 Novartis $35,647
05 AstraZeneca $30,677
06 Merck $25,901
07 Johnson & Johnson $24,567
08 Roche $23,624
09 Eli Lilly & Co. $19,285
10 Bristol-Myers Squibb $17,715
11 Wyeth $17,391
12 Schering-Plough $16,534
13 Abbott Laboratories $16,013
14 Takeda $13,841
15 Bayer Schering $13,803
16 Boehringer Ingelheim $13,405
17 Teva* 10,482
18 Astellas* $9,646
19 Daiichi-Sankyo* $7,900
20 Eisai* $7,612
Based on 2008 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the pipeline and patent expiry info, download the PDFs of the profiles, available within each company's page.
* PDF profiles only available for companies 17-20
Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Bayer-Schering, by Kristin Brooks.
Guest- Guest
Re: Top Pharmaceuticals
Thế nhưng bước sang đầy năm 2010, một báo cáo khác cho thấy có sự thay đổi:
26.03.2010 18:16
FACTBOX-The 20 largest pharmaceutical companies
March 26 (Reuters) - The following is a list of the top 20
pharmaceutical companies, ranked by global prescription drug
sales for the 12 months through September 2009, according to
pharmaceutical market research company IMS Health Inc.
The chart shows sales -- in billions of U.S. dollars -- and
percent change over the period. The data does not include the
results from mega acquisitions by Pfizer and Merck , as their deals for Wyeth and Schering-Plough,
respectively, were completed in the fourth quarter.
A year after a wave of mega-mergers shook up the
pharmaceutical industry, the remaining big drugmakers most
often mentioned as takeout or merger candidates appear set to
go it alone as they edge toward their patent cliffs.
Company Sales (billion US$) % change
1) Pfizer $41.7 (0.
2) Novartis $36.7 + 7.0
3) Sanofi-Aventis $35.1 + 3.3
4) GlaxoSmithKline $34.3 (3.4)
5) AstraZeneca $33.2 + 7.8
6) Roche $31.3 + 8.6
7) Johnson&Johnson $26.9 (6.6)
Merck&Co $25.0 (4.1)
9) Eli Lilly $19.6 + 8.3
10) Abbott $19.4 + 5.5
11) Teva $15.7 + 12.3
12) Bayer $15.4 + 3.9
13) Wyeth $14.8 (2.3)
14) Amgen $14.8 (3.1)
15) Boehringer $14.6 + 10.4
16) Takeda $14.4 + 2.1
17) Bristol-Myers $14.2 + 5.8
18) Schering-Plough $13.1 + 4.3
19) Daiichi Sankyo $8.5 + 3.1
20) Novo Nordisk $8.2 + 11.6
(Source: IMS Health)
26.03.2010 18:16
FACTBOX-The 20 largest pharmaceutical companies
March 26 (Reuters) - The following is a list of the top 20
pharmaceutical companies, ranked by global prescription drug
sales for the 12 months through September 2009, according to
pharmaceutical market research company IMS Health Inc.
The chart shows sales -- in billions of U.S. dollars -- and
percent change over the period. The data does not include the
results from mega acquisitions by Pfizer and Merck , as their deals for Wyeth and Schering-Plough,
respectively, were completed in the fourth quarter.
A year after a wave of mega-mergers shook up the
pharmaceutical industry, the remaining big drugmakers most
often mentioned as takeout or merger candidates appear set to
go it alone as they edge toward their patent cliffs.
Company Sales (billion US$) % change
1) Pfizer $41.7 (0.
2) Novartis $36.7 + 7.0
3) Sanofi-Aventis $35.1 + 3.3
4) GlaxoSmithKline $34.3 (3.4)
5) AstraZeneca $33.2 + 7.8
6) Roche $31.3 + 8.6
7) Johnson&Johnson $26.9 (6.6)
Merck&Co $25.0 (4.1)
9) Eli Lilly $19.6 + 8.3
10) Abbott $19.4 + 5.5
11) Teva $15.7 + 12.3
12) Bayer $15.4 + 3.9
13) Wyeth $14.8 (2.3)
14) Amgen $14.8 (3.1)
15) Boehringer $14.6 + 10.4
16) Takeda $14.4 + 2.1
17) Bristol-Myers $14.2 + 5.8
18) Schering-Plough $13.1 + 4.3
19) Daiichi Sankyo $8.5 + 3.1
20) Novo Nordisk $8.2 + 11.6
(Source: IMS Health)
Guest- Guest
Re: Top Pharmaceuticals
Cập nhật tình hình doanh số các công ty Dược 2014 nhé:
1. J&J, US: 71,3 Bio USD
2. Novartis, Switzerland: 60.9
3. Roche, Switzerland: 52.4
4. Pfizer, U:S 51.6
5. Sanofi, France: 45.8
6. Merck, US: 44
7. GSK, UK: 43.9
8. AZ, UK: 27.2
9. Eli Lilly, US: 23.1
10. Abbott Lab, US: 21.8
http://www.statista.com/statistics/272717/top-global-biotech-and-pharmaceutical-companies-based-on-revenue/
Vậy là Novartis sales hàng thứ 4 nhưng lợi nhuận hàng thứ 2, còn Pfizer tuy sales rất lớn nhưng lợi nhuận lại hàng thứ 4
1. J&J, US: 71,3 Bio USD
2. Novartis, Switzerland: 60.9
3. Roche, Switzerland: 52.4
4. Pfizer, U:S 51.6
5. Sanofi, France: 45.8
6. Merck, US: 44
7. GSK, UK: 43.9
8. AZ, UK: 27.2
9. Eli Lilly, US: 23.1
10. Abbott Lab, US: 21.8
http://www.statista.com/statistics/272717/top-global-biotech-and-pharmaceutical-companies-based-on-revenue/
Vậy là Novartis sales hàng thứ 4 nhưng lợi nhuận hàng thứ 2, còn Pfizer tuy sales rất lớn nhưng lợi nhuận lại hàng thứ 4
Guest- Guest
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Fri Dec 11, 2015 4:40 pm by Guest
» Bệnh mỡ máu cao kiêng ăn gì? Bệnh nhân cần biết
Fri Nov 27, 2015 9:02 pm by Guest
» Các triệu chứng của bệnh lý máu nhiễm mỡ
Thu Nov 19, 2015 4:33 pm by Guest
» Tinh dầu bưởi là như thế nào ? Mua tinh dầu bưởi ở đâu?
Mon Nov 16, 2015 4:41 pm by Guest
» Xà phòng tự nhiên mua ở địa chỉ nào tốt nhất?
Sat Nov 14, 2015 9:37 am by Guest
» Các loại thuốc hạ men gan tin cậy?
Fri Nov 13, 2015 5:10 pm by Guest
» Sản phẩm son kem mua ở đâu uy tín?
Thu Nov 12, 2015 5:45 pm by Guest
» Bệnh lý gan nhiễm mỡ uống thuốc gì thì tốt cho gan?
Sat Nov 07, 2015 3:23 pm by Guest
» Gan nhiễm mỡ và phương pháp điều trị căn bệnh tốt nhất?
Sat Nov 07, 2015 9:19 am by Guest